240 related articles for article (PubMed ID: 35879775)
21. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
Li J; Wang J; Ding Y; Zhao J; Wang W
BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
[TBL] [Abstract][Full Text] [Related]
22.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
23. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
Lin WW; Ou GY; Zhao WJ
J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
25. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses.
Xiao Y; Zhu Z; Li J; Yao J; Jiang H; Ran R; Li X; Li Z
Aging (Albany NY); 2020 Feb; 12(4):3407-3430. PubMed ID: 32081833
[TBL] [Abstract][Full Text] [Related]
26. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
27. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
28. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma.
Lu Z; Chen Y; Chen S; Zhu X; Wang C; Wang Z; Yao Q
Oxid Med Cell Longev; 2022; 2022():1494520. PubMed ID: 36531205
[TBL] [Abstract][Full Text] [Related]
30. DDOST Correlated with Malignancies and Immune Microenvironment in Gliomas.
Chang X; Pan J; Zhao R; Yan T; Wang X; Guo C; Yang Y; Wang G
Front Immunol; 2022; 13():917014. PubMed ID: 35812432
[TBL] [Abstract][Full Text] [Related]
31. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.
Tao C; Luo H; Chen L; Li J; Zhu X; Huang K
Bioengineered; 2021 Dec; 12(1):4016-4031. PubMed ID: 34288803
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
33. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.
Xiao F; Jie X; Zhou X; Guo Y; Sun GF; Lin L; Hu GW; Huang K; Guo H
Biosci Rep; 2023 May; 43(5):. PubMed ID: 37083601
[TBL] [Abstract][Full Text] [Related]
34. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
Front Oncol; 2021; 11():654350. PubMed ID: 33954112
[TBL] [Abstract][Full Text] [Related]
35. A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs.
Kiran M; Chatrath A; Tang X; Keenan DM; Dutta A
Mol Neurobiol; 2019 Jul; 56(7):4786-4798. PubMed ID: 30392137
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.
Wu S; Miao K; Wang L; Ma Y; Wu X
Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel immune-related lncRNA signature to predict prognostic outcome and therapeutic efficacy of LGG.
Wu D; Wang X; Xue Y; Sun C; Zhang M
J Integr Neurosci; 2022 Mar; 21(2):55. PubMed ID: 35364643
[TBL] [Abstract][Full Text] [Related]
38. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
39. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma.
Wang LC; Cui WY; Zhang Z; Tan ZL; Lv QL; Chen SH; Shen XL
Brain Res Bull; 2021 Oct; 175():26-36. PubMed ID: 34280481
[TBL] [Abstract][Full Text] [Related]
40. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.
Jia Y; Cheng X; Liang W; Lin S; Li P; Yan Z; Zhang M; Ma W; Hu C; Wang B; Liu Z
Curr Res Transl Med; 2022 Sep; 70(4):103345. PubMed ID: 35487167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
